Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Expanding Italy’s clinical trial capacities to the rest of the world

05.03.2007
Fondazione Parco Biomedico San Raffaele (PSB), located approximately 15 km south of Rome in a natural reserve, the science park was created by the Banca di Roma, the Chamber of Commerce of Rome, and the Fondazione San Raffaele Monte Tabor in response to the recognised need to have a biomedical research centre in the Lazio region.

Opened in 2002, the park is now home to 3 companies and 9 research groups from Universities and centres working in: Stem cells, Oncology, leukaemia and Immunology; Molecular cardiology; Skeletal regeneration; Cell therapy and tissue engineering; Muscular dystrophies; Biomedical quality control; Neurological Disorders and Diabetes.

The infrastructure permits the development of concept to preclinical development based on the state-of-the-art facilities including a animal facility encompassing conventional and SPF small animals and a large animal surgery unit. The Fondazione has recently created a Lazio based pre-clinical to clinical trial platform with CRISC (http://w3.uniroma1.it/crisc/), and is also in an international biomedical portfolio management project (Transvac) involving the European Clinical Research Infrastructure Network (www.ecrin.org)

Recently PSB formed a mutual agreement with Datapharm Australia (www.datapharm.com.au). Datapharm Australia is established as the most experienced Australian Contract Research Organisation (CRO) (est. 1987). Locally based, internationally connected through ‘research point’ (www.researchpoint.com) , Datapharm Australia provides all or part clinical trial services to suit needs of Biotechnology and ‘Big Pharma’ companies Australia wide.

... more about:
»Australia »Biomedical »Datapharm

This global link aims primarily to:

•Increase overseas interest and awareness of each party’s capabilities (i.e. of Fondazione Parco Biomedico San Raffaele capabilities in Australia and Datapharm Australia’s capabilities in Italy).

•Enable a pipeline/‘support network’ for Australian and Italian/European biotechnology and pharmaceutical companies to utilise each party’s capacities where appropriate.

Although early days, the future advantages of this collaboration are numerous. Both parties will be able to add value for clients who wish to extend operations, research and/or clinical trial programs offshore in new markets. It will also allow a smooth passage for clients from both Europe and Australia to conduct clinical trials and access research opportunities in new markets. Collaboration and strong relations globally are essential to allow access to more patient numbers for global clinical trials whilst maintaining a high standard of quality.

Australia is one of the highest ranked countries for the biotech industry, home to over 420 companies and has many ongoing clinical trials, while Europe boasts over 1400 companies. Traditionally smaller companies have tended to stay close to home in product validation. This collaboration has been created to open the door to conduct more trials on both continents for companies to augment revenue and add value.

“This collaboration moves the Fondazione’s ongoing strategies to enable bench to bedside research into the global arena, and will offer Italian and European entities the possibility to penetrate one of the most dynamic biotech economies on the planet. The existence of the mutual recognition agreement between Europe and Australia for cGMP products will mean that the costs associated with this market penetrance should be significantly lower through the leveraging of the excellence of both partners.

Essentially it strengthens the efforts of both entities to generate a solid system of biomedical diagnostic and therapeutic validation through clinical trials and complements existing globalisation strategies thereby generating global opportunities for resident biotechnology companies.

Essentially it strengthens the efforts of both entities to generate a solid system of biomedical diagnostic and therapeutic validation through clinical trials and complements existing globalisation strategies thereby generating global opportunities for resident biotechnology companies.”

Marco Baccanti, Director General, Fondazione Parco Biomedico San Raffaele

Jonathan Dando | alfa
Further information:
http://www.scienceparkrome.org

Further reports about: Australia Biomedical Datapharm

More articles from Life Sciences:

nachricht Shrews shrink in winter and regrow in spring
24.10.2017 | Max-Planck-Institut für Ornithologie

nachricht 'Y' a protein unicorn might matter in glaucoma
23.10.2017 | Georgia Institute of Technology

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Salmonella as a tumour medication

HZI researchers developed a bacterial strain that can be used in cancer therapy

Salmonellae are dangerous pathogens that enter the body via contaminated food and can cause severe infections. But these bacteria are also known to target...

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

3rd Symposium on Driving Simulation

23.10.2017 | Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

 
Latest News

Shrews shrink in winter and regrow in spring

24.10.2017 | Life Sciences

Microfluidics probe 'cholesterol' of the oil industry

23.10.2017 | Life Sciences

Gamma rays will reach beyond the limits of light

23.10.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>